関連する実験動画
Updated: May 11, 2026
07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 16, 2010
組織のエンドセリン変換酵素の活動は,冠動脈疾患における心血管リスク因子と相関しています
F Ruschitzka1, U Moehrlen, T Quaschning
1Cardiology, University Hospital and Cardiovascular Research, Institute of Physiology, University of Zürich, Switzerland.
Circulation
|September 7, 2000
まとめ
血管内ドセリン変換酵素 (ECE) の活動は,心血管疾患の危険因子と関連しています. 低ECE活動は,高いLDLコレステロールと高血圧と相関しており,冠動脈疾患の進行における役割を示唆しています.
科学分野:
- 心血管生物学 心血管生物学
- 酵素学 酵素学とは
- 血管生理学 血管生理学
背景:
- エンドセリン変換酵素 (ECE) は,エンドセリン-1 (ET-1) の生成に不可欠です.
- 心血管疾患 (CVD) の病理生理学におけるECEの特定の役割は完全に理解されていません.
研究 の 目的:
- 冠動脈疾患 (CAD) の患者における血管ECE活動と心血管リスク因子の関係を調査する.
- 低密度脂質タンパク質 (LDL) と酸化されたLDLが,ヒト内皮細胞のECE-1タンパク質レベルに与える影響を調査する.
主な方法:
- CAD患者の内部乳腺動脈 (IMA) とサフェノス静脈 (SV) の大きなエンドセリン-1 (bigET-1) とET-1に対する血管反応性を調べました.
- 血管のECE活動,組織のbigET-1およびET-1レベル,およびECE-1タンパク質発現を評価した.
- 血清のLDLレベル,血圧,および線維生素と相関するECE活動.
主要な成果:
- 血管のECE活動は,IMAにおける血清のLDLレベルと血圧と逆に相関していた.
- フィブリノゲンは,IMAとSVの両方のECE活動と正に相関していました.
- LDLと酸化LDLは,ヒトのIMA内皮細胞におけるECE-1タンパク質レベルを低下させた.
結論:
- 血管のECE活動は,LDLレベルと血圧と逆相関しており,ヒトの血管組織におけるフィブリノゲンと正に関連しています.
- ECE-1の活動は,CAD患者の心血管リスクを調節する上で重要な役割を果たす可能性があります.
関連する概念動画
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...